552 related articles for article (PubMed ID: 31727290)
21. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; de Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V;
J Am Soc Nephrol; 2020 May; 31(5):1128-1139. PubMed ID: 32354987
[TBL] [Abstract][Full Text] [Related]
22. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
[TBL] [Abstract][Full Text] [Related]
23. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
Gonzalez DE; Foresto RD; Ribeiro AB
Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
[TBL] [Abstract][Full Text] [Related]
24. Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A
Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock C; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL
J Am Soc Nephrol; 2020 Dec; 31(12):2925-2936. PubMed ID: 32998938
[TBL] [Abstract][Full Text] [Related]
25. Cardiorenal Protection in Diabetic Kidney Disease.
Lee JF; Berzan E; Sridhar VS; Odutayo A; Cherney DZI
Endocrinol Metab (Seoul); 2021 Apr; 36(2):256-269. PubMed ID: 33873265
[TBL] [Abstract][Full Text] [Related]
26. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
27. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
28. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors and underlying mechanisms.
Kashihara N; Kidokoro K; Kanda E
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):112-118. PubMed ID: 31725011
[TBL] [Abstract][Full Text] [Related]
29. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
Almaimani M; Sridhar VS; Cherney DZI
Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):474-481. PubMed ID: 34074889
[TBL] [Abstract][Full Text] [Related]
30. Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
Stephens JW; Brown KE; Min T
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():32-45. PubMed ID: 32267078
[TBL] [Abstract][Full Text] [Related]
31. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
Woo VC
Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
[TBL] [Abstract][Full Text] [Related]
33. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bae JH; Park EG; Kim S; Kim SG; Hahn S; Kim NH
Sci Rep; 2019 Sep; 9(1):13009. PubMed ID: 31506585
[TBL] [Abstract][Full Text] [Related]
34. Minireview: are SGLT2 inhibitors heart savers in diabetes?
Grubić Rotkvić P; Cigrovski Berković M; Bulj N; Rotkvić L
Heart Fail Rev; 2020 Nov; 25(6):899-905. PubMed ID: 31410757
[TBL] [Abstract][Full Text] [Related]
35. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
Sano M; Goto S
Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
[No Abstract] [Full Text] [Related]
36. [Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].
Scheen AJ
Rev Med Liege; 2019 Oct; 74(10):508-513. PubMed ID: 31609553
[TBL] [Abstract][Full Text] [Related]
37. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
Reid T
J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
[TBL] [Abstract][Full Text] [Related]
38. Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes.
van Raalte DH; Bjornstad P
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i24-i32. PubMed ID: 32003832
[TBL] [Abstract][Full Text] [Related]
39. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
40. Impact of CVOTs in primary and secondary prevention of kidney disease.
De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
